| From molecules to medicine: a future cure for preeclampsia? | |
| | |
MedLine Citation:
|
PMID: 20072730 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
In the United States, preeclampsia (PreE) affects 5-7% of all pregnancies, yet represents 15% of all maternal-fetal morbidity and mortality. PreE causes fetal growth restriction, oligohydramnios, fetal death, and maternal seizures, stroke, cerebrovascular hemorrhage and death. It has immediate and potentially long-term effects on both the fetus and mother. To date, the molecular pathogenesis of PreE is largely unknown. Multiple pathways, including dysfunctional angiogenesis, inappropriate placentation, oxidative stress and an altered immunological milieu have been proposed as key players in the development of PreE. In addition, genetic factors in all of these pathways are essential components in the etiology of this disease. This review introduces the clinical presentation of PreE and its particular disease phenotype that has prompted some of the molecular investigations of its etiology. Evidence of the many molecular pathways involved in the pathogenesis of PreE, as well as the therapeutic investigations targeting these pathways, is presented. |
| | |
Authors:
|
Mark K Santillan; Donna A Santillan; Curt D Sigmund; Stephen K Hunter |
Publication Detail:
|
Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review |
Journal Detail:
|
Title: Drug news & perspectives Volume: 22 ISSN: 0214-0934 ISO Abbreviation: Drug News Perspect. Publication Date: 2009 Nov |
Date Detail:
|
Created Date: 2010-01-14 Completed Date: 2010-03-29 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8809164 Medline TA: Drug News Perspect Country: Spain |
Other Details:
|
Languages: eng Pagination: 531-41 Citation Subset: IM |
Copyright Information:
|
Copyright 2009 Prous Science, S.A.U. or its licensors. All rights reserved. |
Affiliation:
|
Department of Obstetrics and Gynecology, Division of Maternal Fetal Medicine, University of Iowa Hospitals and Clinics, University of Iowa Roy J. and Lucille A. Carver College of Medicine, Iowa City, Iowa, USA. mark-santillan@uiowa.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Antihypertensive Agents / chemistry, pharmacology, therapeutic use* Drug Design* Endothelium, Vascular / drug effects, physiopathology Female Genetic Predisposition to Disease Humans Immune System / drug effects, physiopathology Oxidative Stress Phenotype Placenta / drug effects, physiopathology Pre-Eclampsia / drug therapy*, etiology, physiopathology Pregnancy Risk Factors Signal Transduction / drug effects* |
| Grant Support | |
ID/Acronym/Agency:
|
5-KL2-RR024980-2/RR/NCRR NIH HHS; 5-UL-1RR024979-2/RR/NCRR NIH HHS; AI-07260-22/AI/NIAID NIH HHS; P01 HL084207/HL/NHLBI NIH HHS; T32 HL1007121/HL/NHLBI NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Antihypertensive Agents |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Blocking conversion of GABAergic inhibition as a potential mechanism of propofol-mediated brain prot...
Next Document: The value of anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis: Do they imply new...